Pfizer (NYSE:PFE) has announced that the Phase 3 ELEVATE 12 study of etrasimod met primary and key secondary endpoints. The primary endpoint in the trial involved clinical remission in patients with severely active ulcerative colitis (UC) at week 12. Etrasimod is an experimental once-daily selective sphingosine 1-phosphate (S1P) receptor modulator similar to Bristol-Myers Squibb’s Zeposia…